Ferumoxytol is a nano-sized iron oxide particle approved for iron replacement therapy and may be used off label as an MRI contrast agent. While gadolinium-based contrast agents leak into the brain parenchyma where the blood brain barrier is not intact several minutes after administration, ferumoxytol remains intravascular for hours due to its high molecular weight, enabling excellent vascular visualization, with visible parenchymal enhancement peaking 24 hours after administration. In this study, we compared ferumoxytol T1 enhancement to standard of care gadoteridol enhancement with a quantitative method, which is an important step to develop ferumoxytol as an alternative MR imaging agent.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords